Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production

Published on Apr 29, 2011in PLOS ONE2.74
· DOI :10.1371/JOURNAL.PONE.0019499
Michael A. Curran24
Estimated H-index: 24
(MSK: Memorial Sloan Kettering Cancer Center),
Michael A. Curran15
Estimated H-index: 15
(MSK: Memorial Sloan Kettering Cancer Center)
+ 2 AuthorsJames P. Allison125
Estimated H-index: 125
(MSK: Memorial Sloan Kettering Cancer Center)
Sources
Abstract
Background The co-inhibitory receptor Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) attenuates immune responses and prevent autoimmunity, however, tumors exploit this pathway to evade the host T-cell response. The T-cell co-stimulatory receptor 4-1BB is transiently upregulated on T-cells following activation and increases their proliferation and inflammatory cytokine production when engaged. Antibodies which block CTLA-4 or which activate 4-1BB can promote the rejection of some murine tumors, but fail to cure poorly immunogenic tumors like B16 melanoma as single agents. Methodology/Principal Findings We find that combining αCTLA-4 and α4-1BB antibodies in the context of a Flt3-ligand, but not a GM-CSF, based B16 melanoma vaccine promoted synergistic levels of tumor rejection. 4-1BB activation elicited strong infiltration of CD8+ T-cells into the tumor and drove the proliferation of these cells, while CTLA-4 blockade did the same for CD4+ effector T-cells. Anti-4-1BB also depressed regulatory T-cell infiltration of tumors. 4-1BB activation strongly stimulated inflammatory cytokine production in the vaccine and tumor draining lymph nodes and in the tumor itself. The addition of CTLA-4 blockade further increased IFN-γ production from CD4+ effector T-cells in the vaccine draining node and the tumor. Anti 4-1BB treatment, with or without CTLA-4 blockade, induced approximately 75% of CD8+ and 45% of CD4+ effector T-cells in the tumor to express the killer cell lectin-like receptor G1 (KLRG1). Tumors treated with combination antibody therapy showed 1.7-fold greater infiltration by these KLRG1+CD4+ effector T-cells than did those treated with α4-1BB alone. Conclusions/Significance This study shows that combining T-cell co-inhibitory blockade with αCTLA-4 and active co-stimulation with α4-1BB promotes rejection of B16 melanoma in the context of a suitable vaccine. In addition, we identify KLRG1 as a useful marker for monitoring the anti-tumor immune response elicited by this therapy. These findings should aid in the design of future trials for the immunotherapy of melanoma.
Figures & Tables
Download
📖 Papers frequently viewed together
12.2k Citations
7,635 Citations
1,400 Citations
References24
Newest
#1Michael A. Curran (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 15
#1Michael A. CurranH-Index: 24
Last. James P. AllisonH-Index: 125
view all 4 authors...
Vaccination with irradiated B16 melanoma cells expressing either GM-CSF (Gvax) or Flt3-ligand (Fvax) combined with antibody blockade of the negative T-cell costimulatory receptor cytotoxic T-lymphocyte antigen-4 (CTLA-4) promotes rejection of preimplanted tumors. Despite CTLA-4 blockade, T-cell proliferation and cytokine production can be inhibited by the interaction of programmed death-1 (PD-1) with its ligands PD-L1 and PD-L2 or by the interaction of PD-L1 with B7-1. Here, we show that the com...
1,400 CitationsSource
#1Michael A. CurranH-Index: 15
#1Michael A. CurranH-Index: 24
Last. James P. AllisonH-Index: 125
view all 2 authors...
The transformation of a healthy cell into a malignant neoplasm involves numerous genetic mutations and aberrations in gene expression. As few of these changes are shared between individuals or types of cancer, the best source for eliciting broad-spectrum tumor immunity remains each patient9s own tumor. Previously, we have shown that combining blockade of the T-cell–negative costimulatory molecule CTL-associated antigen 4 (CTLA-4) and vaccination with irradiated B16 tumor expressing granulocyte m...
165 CitationsSource
#1Karl S. Peggs (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 20
#2Sergio A. Quezada (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 45
Last. James P. Allison (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 125
view all 5 authors...
Cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) is a critical negative regulator of immune responses. Uniquely among known inhibitory receptors, its genetic ablation results in a fulminating and fatal lymphoproliferative disorder. This central regulatory role led to the development of antibodies designed to block CTLA-4 activity in vivo, aiming to enhance immune responses against cancer. Despite their preclinical efficacy and promising clinical activity against late stage metastatic melanom...
793 CitationsSource
#1Chao Wang (U of T: University of Toronto)H-Index: 22
#1Chao Wang (U of T: University of Toronto)H-Index: 34
Last. Tania H. Watts (U of T: University of Toronto)H-Index: 45
view all 4 authors...
SUMMARY: The tumor necrosis factor receptor family member 4-1BB plays a key role in the survival of activated and memory CD8(+) T cells. Depending on the disease model, 4-1BB can participate at different stages and influence different aspects of the immune response, likely due to the differential expression of receptor and ligand relative to other costimulatory molecules. Studies comparing mild versus severe influenza infection of mice suggest that the immune system uses inducible receptors such...
268 CitationsSource
#1Mark P. Rubinstein (UCSD: University of California, San Diego)H-Index: 25
#2Nicholas A. Lind (UCSD: University of California, San Diego)H-Index: 3
Last. Ananda W. Goldrath (UCSD: University of California, San Diego)H-Index: 49
view all 8 authors...
Although it is known that interleukin-7 (IL-7) and IL-15 influence the survival and turnover of CD8+ T cells, less is known about how these cytokines affect different subsets during the course of the immune response. We find that IL-7 and IL-15 differentially regulate CD8+ T-cell subsets defined by KLRG1 and CD127 expression during the contraction phase of the immune response. The provision of IL-15, or the related cytokine IL-2, during contraction led to the preferential accumulation of KLRG1hi...
164 CitationsSource
#1Kajsa Wing (Kyoto University)H-Index: 23
#2Yasushi Onishi (Kyoto University)H-Index: 23
Last. Shimon Sakaguchi (Kyoto University)H-Index: 107
view all 8 authors...
Naturally occurring Foxp3 + CD4 + regulatory T cells (Tregs) are essential for maintaining immunological self-tolerance and immune homeostasis. Here, we show that a specific deficiency of cytotoxic T lymphocyte antigen 4 (CTLA-4) in Tregs results in spontaneous development of systemic lymphoproliferation, fatal T cell–mediated autoimmune disease, and hyperproduction of immunoglobulin E in mice, and it also produces potent tumor immunity. Treg-specific CTLA-4 deficiency impairs in vivo and in vit...
2,960 CitationsSource
#1Jedd D. Wolchok (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 119
#2Yvonne M. Saenger (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 2
The survival rate of patients diagnosed with late-stage melanoma is poor—only 5%–10%. Enlisting the immune system in the fight against cancers such as melanoma could help improve the prognosis of these patients. Data have shown that melanocyte proteins make good targets for immune system–based therapy in this disease. However, self-tolerance, which develops to inhibit autoimmune attack, makes this strategy difficult. Two
216 CitationsSource
#1Juliet C. Gray (University of Southampton)H-Index: 10
#2Ruth R. French (University of Southampton)H-Index: 31
Last. Martin J. Glennie (University of Southampton)H-Index: 58
view all 6 authors...
Immunostimulatory mAb as vaccine adjuvants for the treatment of cancer hold considerable potential for boosting weak responses when used against immunogenic tumours, or in combination with various other vaccines. We now show that when administered with OVA, the combination of anti-4-1BB mAb with anti-CD40, anti-OX40 or anti-CD25 resulted in a fourfold enhancement in the antigen-specific T-cell response compared with anti-4-1BB mAb alone, with a similar enhancement in memory responses following r...
95 CitationsSource
#1Kutlu G. Elpek (University of Louisville)H-Index: 25
#2Esma S. Yolcu (University of Louisville)H-Index: 24
Last. Haval Shirwan (University of Louisville)H-Index: 27
view all 6 authors...
Naturally occurring CD4+CD25+FoxP3+ T regulatory (Treg) cells require three distinct signals transduced via TCR, CD28, and IL-2R for their development and maintenance. These requirements served as the basis for several recently developed ex vivo expansion protocols that relied on the use of solid support-bound Abs to CD3 and CD28 in the presence of high dose IL-2. We report in this study that Treg cells up-regulate the expression of inducible costimulatory receptor 4-1BB in response to IL-2, and...
175 CitationsSource
#1Niklas Beyersdorf (University of Würzburg)H-Index: 21
#2Xin Ding (University of Würzburg)H-Index: 5
Last. Thomas Hanke (University of Würzburg)H-Index: 1
view all 4 authors...
The mouse killer cell lectin-like receptor G1 (KLRG1) is an inhibitory receptor known to be expressed on a subset of NK cells and antigen-experienced CD8 T cells. Here, we have characterized expression of KLRG1 on CD4+ T cells from normal mice. While a polyclonal TCR repertoire suggests thymic origin of KLRG1+ CD4+ cells, KLRG1 expression was found to be restricted to peripheral CD4+ T cells. Based on phenotypic analyses, a minority of KLRG1+ CD4+ cells are effector/memory cells with a prolifera...
73 CitationsSource
Cited By176
Newest
#2Atieh Pourbagheri-Sigaroodi (IUMS: Iran University of Medical Sciences)
Last. Davood BashashH-Index: 15
view all 6 authors...
Although immunosurveillance mechanisms are doing their best to counteract with the development of malignant cells, immune checkpoints may serve as the "Achilles' heel" that are exploited by malignant cells. Notably, a deep understanding of this fragile site of the immune system later led to the development of immune checkpoint blockades (ICBs). At the beginning of the discovery, it seemed that these agents could push the boundaries of cancer treatment, however, their life-threatening adverse eve...
Source
#1Jesse Armitage (UWA: University of Western Australia)H-Index: 2
Last. Jason WaithmanH-Index: 21
view all 5 authors...
Immunotherapy has revolutionised the treatment of cancers by harnessing the power of the immune system to eradicate malignant tissue. However, it is well recognised that some cancers are highly resistant to these therapies, which is in part attributed to the immunosuppressive landscape of the tumour microenvironment (TME). The contexture of the TME is highly heterogeneous and contains a complex architecture of immune, stromal, vascular and tumour cells in addition to acellular components such as...
Source
#1Shan He (Fudan University)H-Index: 1
#2Jinhua Xu (Fudan University)H-Index: 14
Last. Jinfeng Wu (Fudan University)H-Index: 21
view all 3 authors...
Source
#1Ashvin R. Jaiswal (University of Texas MD Anderson Cancer Center)H-Index: 7
#2Arthur Liu (University of Texas MD Anderson Cancer Center)H-Index: 4
Last. Michael A. Curran (University of Texas MD Anderson Cancer Center)H-Index: 24
view all 20 authors...
Despite the clinical success of T-cell checkpoint blockade, most patients with cancer still fail to have durable responses to immunotherapy. The molecular mechanisms driving checkpoint blockade resistance, whether preexisting or evolved, remain unclear. To address this critical knowledge gap, we treated B16 melanoma with the combination of CTLA-4, PD-1, and PD-L1 blockade and a Flt3 ligand vaccine (≥75% curative), isolated tumors resistant to therapy, and serially passaged them in vivo with the ...
1 CitationsSource
#1Daniel Almquist (Mayo Clinic)H-Index: 2
#2Daniel H. Ahn (Mayo Clinic)H-Index: 17
Last. Tanios Bekaii-Saab (Mayo Clinic)H-Index: 45
view all 3 authors...
Over the past decade, immune checkpoint inhibitors (ICI) have proven to be promising agents in a number of solid tumor malignancies. Pembrolizumab and nivolumab are ICIs that target programmed cell death protein 1 and both have been approved by the US Food and Drug Administration for the treatment of microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) colorectal cancer (CRC). In MSI-H/dMMR CRC, these agents were found to have considerable antitumor activity and are now use...
Source
#1Michael J. Gough (Providence Portland Medical Center)H-Index: 34
#2Shay Sharon (HUJI: Hebrew University of Jerusalem)H-Index: 2
Last. Kristina H. Young (Providence Portland Medical Center)H-Index: 11
view all 4 authors...
Immunotherapies are rapidly entering the clinic as approved treatments for diverse cancer pathologies. Radiation therapy is an integral partner in cancer therapy, commonly as part of complicated multimodality approaches that optimize patient outcomes. Preclinical studies have demonstrated that the success of radiation therapy in tumor control is due in part to immune mechanisms, and that outcomes following radiation therapy can be improved through combination with a range of immunotherapies. How...
1 CitationsSource
Overcoming tolerance to tumor-associated antigens remains a hurdle for cancer vaccine-based immunotherapy. A strategy to enhance the anti-tumor immune response is the inclusion of adjuvants to cancer vaccine protocols. In this report, we generated and systematically screened over twenty gene-based molecular adjuvants composed of cytokines, chemokines, and T cell co-stimulators for the ability to increase anti-tumor antigen T cell immunity. We identified several robust adjuvants whose addition to...
Source
#1Jason Williams (Brigham and Women's Hospital)H-Index: 1
#2Thomas S. Kupper (Brigham and Women's Hospital)H-Index: 79
Source
#1Matthew Reilley (UVA: University of Virginia)H-Index: 2
#1Matthew J. Reilley (UVA: University of Virginia)H-Index: 7
Last. Michael A. Curran (University of Texas at Austin)H-Index: 15
view all 6 authors...
Tumors that lack pre-existing immune infiltration respond poorly to T cell checkpoint blockade immunotherapy. These cancers often surround themselves with high densities of suppressive myeloid stroma while excluding immunostimulatory dendritic cells. Tumor-resident myeloid cells and selected lymphocyte populations retain expression of Toll-like Receptors (TLR) that sense common features of pathogens and activate innate immunity in response. We explored whether agonists of TLR9 could augment inna...
9 CitationsSource
#1Sarah A. Weiss (Yale University)H-Index: 14
#2Jedd D. Wolchok (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 119
Last. Mario Sznol (Yale University)H-Index: 64
view all 3 authors...
Melanoma is among the most sensitive of malignancies to immune modulation. Although multiple trials conducted over decades with vaccines, cytokines and cell therapies demonstrated meaningful responses in a small subset of patients with metastatic disease, a true increase in overall survival within a randomized phase 3 trial was not observed until the development of anti-CTLA-4 (ipilimumab). Further improvements in overall survival for metastatic disease were observed with the anti-PD-1-based the...
44 CitationsSource